Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Appointed director
|
|
APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2022 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021 -Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., February 14, 2022 — Applied Genetic Technologies Corporation , a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus -based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases , today announced financial results for the quarter ended December 31, 2021. “We enter 2022 with significant momentum from the recent buildout of our management team, completion and reporting of several milestones, ..." |
|
| 11/09/2021 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 9, 2021 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace Suite 10 Alachua, Florida, 32165 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicat...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021 -Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 9, 2021 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare inherited retinal diseases , today announced financial results for the quarter ended September 30, 2021. “We have significant momentum toward achieving multiple clinical and regulatory milestones in the year ahead. We believe that the data we have generated to date in the Phase 1/2 XLRP clinical tria..." |
|
| 09/23/2021 |
8-K
| Quarterly results |
| 05/17/2021 |
8-K
| Quarterly results |
| 11/16/2020 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 16, 2020 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace Suite 10 Alachua, Florida, 32165 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communica...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020 GAINESVILLE, Fla., and CAMBRIDGE, Mass., November 16, 2020 - Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2020. The Company is also providing an update on its ongoing clinical trials in patients with X-linked retinitis pigmentosa and achromatopsia . “The updated XLRP data that we reported last week provide evidence that our XLRP product candidate provides durable improvements in visual sensitivity and visual acuity over a wide dose range and has a favorable safety profile,” said Sue Washer, P..." |
|
| 09/09/2020 |
8-K
| Investor presentation, Quarterly results |
| 05/13/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 09/26/2019 |
8-K
| Investor presentation, Quarterly results |
| 05/07/2019 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 7, 2019 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace, Suite 10, Alachua, Florida 32615 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications p...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019 GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 7, 2019 - Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2019. “Completing enrollment in the dose escalation portion of our Phase 1/2 trial in patients with achromatopsia due to mutations in the CNGB3 gene and the expansion cohort of our Phase 1/2 trial in patients with X-linked retinitis pigmentosa demonstrates our clinical development progress and keeps us on track to report multiple data sets in the second half of 2019,” said Sue Washer, President and CEO..." |
|
| 02/07/2019 |
8-K
| Quarterly results |
| 11/08/2018 |
8-K
| Quarterly results|
Docs:
|
"SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 8, 2018 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace Suite 10 Alachua, Florida, 32165 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant ...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018 GAINESVILLE, Fla., and CAMBRIDGE, Mass., November 8, 2018 - Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2018. “Advancing our diversified pipeline of differentiated product candidates continues to be a key priority, and I am pleased with the progress we are making toward that goal,” said Sue Washer, President and CEO of AGTC. “Our four clinical-stage programs, all of which are designed to provide significant clinical benefits to patients with rare ophthalmic diseases offer multiple opportunit..." |
|
| 09/10/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 02/09/2018 |
8-K
| Quarterly results|
Docs:
|
"SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : February 9, 2018 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace Suite 10 Alachua, Florida, 32165 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant ...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017 GAINESVILLE, Fla., and CAMBRIDGE, Mass., February 9, 2018 - Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2017. “Our primary focus for 2018 is enrolling patients in the company's ongoing Phase 1/2 clinical trials for our XLRS, ACHM and XLRP product candidates,” said Sue Washer, President and CEO of AGTC. “We have taken steps to add clinical staff, employ additional resources and increase awareness of our trials through patient advocacy. These efforts have already resulted in more patients enteri..." |
|
| 11/07/2017 |
8-K
| Quarterly results|
Docs:
|
"SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 7, 2017 APPLIED GENETIC TECHNOLOGIES CORPORATION Delaware 001-36370 59-3553710 14193 NW 119 th Terrace Suite 10 Alachua, Florida, 32165 462-2204 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions . ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant ...",
"AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 GAINESVILLE, Fla., and CAMBRIDGE, Mass., November 7, 2017 - Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2017. “Progressing our XLRS, XLRP and ACHM clinical studies is our primary focus, while continuing to develop our corporate infrastructure to support these programs and our research efforts in vector design and manufacturing,” said Sue Washer, President and CEO of AGTC. Recent Highlights" |
|
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 02/08/2017 |
8-K
| Form 8-K - Current report |
| 11/08/2016 |
8-K
| Quarterly results |
| 09/12/2016 |
8-K
| Form 8-K - Current report |
| 05/09/2016 |
8-K
| Form 8-K - Current report |
| 02/08/2016 |
8-K
| Form 8-K - Current report |
| 11/05/2015 |
8-K
| Form 8-K - Current report |
| 05/11/2015 |
8-K
| Form 8-K - Current report |
| 02/11/2015 |
8-K
| Form 8-K - Current report |
| 11/12/2014 |
8-K
| Form 8-K - Current report |
|
|